What Else Is Under the Hood for Catalyst Pharma?
ThinkstockCatalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) announced positive topline results from its Phase 3 clinical trial of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. In the study, Firdapse was reported…